Drug Database
RO

rosuvastatin + ezetimibe (ID 1805 / ID1805 / Droptop)

✓ Approved

Ildong Pharmaceutical · HMGCR · 小分子

什么是 rosuvastatin + ezetimibe?

rosuvastatin + ezetimibe 是一种小分子,由Ildong Pharmaceutical研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)。

药物档案

商品名ID 1805, ID1805, Droptop
公司Ildong Pharmaceutical
药物类别小分子
分子靶点HMGCR, NPC1L1
给药途径Oral (PO)
状态Approved

作用机制

分子靶点

rosuvastatin + ezetimibe 作用于 2 个分子靶点:

HMGCR3-hydroxy-3-methylglutaryl-CoA reductase (LDLCQ3, LGMDR28)
NPC1L1NPC1 like intracellular cholesterol transporter 1 (SLC65A2, LDLCQ7)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

rosuvastatin + ezetimibe 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Metabolism and nutrition disordersHypercholesterolaemia✓ Approved

相关研究文献

PubMedAssay and drug development technologies2026-11-18

Next-Generation Oleic Acid Ufasomes: Emerging Trends in Targeted, Controlled, and Stimuli-Responsive Drug Delivery Systems.

Komal, Singh Lovekesh L

Ufasomes are vesicles formed from unsaturated fatty acids and are being investigated as carriers for pharmaceutical compounds. This review summarizes their structure, preparation methods, characterization, drug-release behavior, and emerging applications, with particular attention to reported studies involving rosuvastatin for diabetic wound healing, nintedanib for pulmonary delivery, and Glycyrrhiza glabra extract in wound dressings. Despite promising preclinical findings, translation remains limited by potential of hydrogen-dependent stability, challenges in reproducible scale-up, and insufficient safety and clinical evidence. The review critically considers these findings and identifies priorities for further development.

PMID 43046960
阅读全文 →
PubMedThe American journal of cardiology2026-11-18

Effect of High-Intensity Statin Therapy on Coronary Plaque Composition Assessed by Machine Learning-Based Optical Coherence Tomography Analysis.

Saboe Aninka A, García-García Héctor M HM, Rubio Pablo P, Bakir Eren Ozan EO et al.

The value of artificial intelligence (AI)-assisted optical coherence tomography (OCT) for assessing longitudinal changes in coronary plaque composition remains uncertain. We performed a post hoc, vessel-level substudy of the Integrated Biomarkers and Imaging Study-4 (IBIS-4), using AI-assisted tissue characterization of serial OCT images from nonculprit coronary vessels in patients with ST-segment elevation myocardial infarction treated with high-intensity rosuvastatin. Baseline and follow-up measurements were compared using paired nonparametric analyses. Serial analyzable imaging was available in 45 vessels from 33 patients. Minimum fibrous-cap thickness increased from 93.98 to 117.26 μm (p = 0.027), and mean cap thickness increased from 309.20 to 353.12 μm (p < 0.001). Lipid volume decreased from 28.36 to 22.88 mm³ (p = 0.002), and the relative lipid component decreased from 18.34% to 17.06% (p = 0.044). Relative fibrous tissue percentage increased from 70.10% to 74.52% (p = 0.001), whereas absolute fibrous tissue volume did not significantly change. Calcification volume did not significantly change (p = 0.307), but relative calcific burden increased from 7.60% to 8.49% (p = 0.020). In conclusion, AI-assisted analysis of serial IBIS-4 OCT imaging reproduced a plaque-stabilization signature characterized by fibrous-cap thickening, lower lipid burden, and increased calcific signal after high-intensity statin therapy, supporting further study of AI-assisted plaque analysis in longitudinal coronary imaging investigations.

PMID 43051348
阅读全文 →
PubMedAtherosclerosis plus2026-11-16

Simulation of low-density lipoprotein cholesterol goal attainment with treatment intensification in a population with homozygous familial hypercholesterolemia.

Koumas Alexandra A, Sriprada Tupili Sravya TS, Sanchez Robert J RJ, Tripathi Sandeep S et al.

Most people with homozygous familial hypercholesterolemia (HoFH) do not achieve guideline-recommended low-density lipoprotein cholesterol (LDL-C) goals despite standard-of-care (SOC) lipid-lowering therapies (LLTs). Here, we estimate the proportion of individuals with HoFH achieving guideline-recommended LDL-C goals of <100 mg/dL, <70 mg/dL, and <55 mg/dL after treatment intensification. A simulation model explored LLT intensification strategies with statin, ezetimibe, proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9is), evinacumab, lomitapide, and/or lipoprotein apheresis for LDL-C goal attainment. Baseline LLTs and LDL-C levels were obtained from 78 participants with HoFH in the CASCADE FH registry. Adding evinacumab or lomitapide (10 mg/day) to SOC enabled an estimated 80.1% and 59.3% of individuals to reach LDL-C <100 mg/dL, respectively; biweekly apheresis plus SOC enabled 65.4%. Combining evinacumab and apheresis with SOC raised attainment of <100 mg/dL to 95.6%, and adding lomitapide further increased attainment to 96.7%. For more stringent goals of LDL-C <70 mg/dL and <55 mg/dL, 50.9% and 29.8% of individuals achieved these goals with evinacumab plus SOC, respectively, and 80.8% and 64.6% with evinacumab and apheresis plus SOC. Combining all three advanced therapies (evinacumab, lomitapide, and apheresis) with SOC enabled most people to reach goals of <70 mg/dL (92.4%) and <55 mg/dL (79.7%). Simulation findings indicate that most people with HoFH require aggressive treatment intensification with advanced LLTs to achieve guideline-recommended LDL-C goals. Evinacumab with/without apheresis or lomitapide represents a highly effective treatment strategy. Our findings support earlier escalation to advanced LLTs when SOC is unlikely to be sufficient.

PMID 43036356
阅读全文 →
PubMedPloS one2026-11-16

Guideline-directed discharge medication patterns and post-discharge outcomes in older patients with acute coronary syndrome and multivessel coronary disease: A real-world observational study.

Dang Hai Nguyen Ngoc HNN, Nguyen Hung Minh HM, Tran Phuc Thien PT, Ho Binh Anh BA et al.

Guideline-directed medical therapy is central to secondary prevention after acute coronary syndrome (ACS), but recommendations are usually framed at the medication-class level. In discharge practice, clinicians must select individual agents, especially in older patients with multivessel coronary disease. This study described discharge prescribing patterns and examined associations between within-class medication choices and short-term major adverse cardiovascular events (MACE). This prospective, multicenter, real-world observational cohort included 277 patients aged ≥60 years with ACS and multivessel coronary disease. The primary outcome was 3-month MACE. Risk ratios (RRs) were estimated using modified Poisson regression with robust standard errors. Core secondary prevention therapies were frequently prescribed, including dual antiplatelet therapy in 99.3% and statins in 99.6%. In fully adjusted within-class analyses, ticagrelor versus clopidogrel had an RR of 0.70 for short-term MACE (95% CI, 0.40-1.21; P = 0.203), empagliflozin versus dapagliflozin had an RR of 1.55 (95% CI, 0.93-2.59; P = 0.094), and rosuvastatin versus atorvastatin had an RR of 1.21 (95% CI, 0.79-1.85; P = 0.372). Exploratory subgroup analyses showed nominal signals for ticagrelor versus clopidogrel among patients with frailty (RR, 0.36; 95% CI, 0.15-0.89; P = 0.026), and for empagliflozin versus dapagliflozin among patients with left ventricular ejection fraction <50% (RR, 1.86; 95% CI, 1.07-3.21; P = 0.027) and non-ST-segment elevation acute coronary syndrome (RR, 2.26; 95% CI, 1.05-4.88; P = 0.037). However, none remained statistically significant after adjustment for multiple comparisons. In older patients with ACS and multivessel disease, secondary prevention was widely implemented. Within-class comparisons showed no clear short-term MACE differences, while subgroup signals require validation.

PMID 43038200
阅读全文 →
PubMedFrontiers in pharmacology2026-11-15

Atorvastatin-associated liver injury: a structured narrative review of reporting signals, clinical phenotypes, and hepatic safety, 2023-2026.

Zhang Hao H, Zhao PanLi P, Huang Hua H, Zeng YuQi Y

Atorvastatin is widely prescribed, yet its hepatic safety remains debated: randomized trials and biopsy-proven cohorts indicate acceptable safety, whereas pharmacovigilance data and case reports describe injury ranging from asymptomatic transaminase elevation to acute liver failure. PubMed was searched for records combining atorvastatin terms with liver-injury concepts, published 1 July 2023 to 31 July 2026; records were screened in duplicate and assigned to one of four outcome domains-biochemical liver test abnormality, suspected drug-induced liver injury (DILI), clinically significant or severe DILI, and acute liver failure-and were not combined across domains. This is a structured narrative review, not a systematic review: only PubMed was searched and comprehensive retrieval is not claimed. Of 119 records, 57 were included in the synthesis: 31 directly addressed atorvastatin and liver injury and 26 addressed statin hepatic safety or statin use in chronic liver disease. Among 7,779 statin-associated drug-induced liver injury (DILI) cases in FAERS (2004-2023), atorvastatin accounted for 53.48%, with a reporting odds ratio of 3.09. In 1 211 reported Chinese cases of statin-associated liver injury, the odds of severe injury were 1.77-fold higher with atorvastatin than with rosuvastatin, and 2.08-fold higher with combination therapy than with statin monotherapy. Phenotypes included hepatocellular, cholestatic and mixed injury, drug-induced autoimmune hepatitis (DIAIH) and hyperacute liver failure, usually within 2-3 months. Rechallenge reproduced injury in 12 of 16 cases, with median latency shortened from 27 to 11 days, whereas switching to a hydrophilic statin was usually tolerated. Mechanisms involve mitochondrial dysfunction, oxidative stress, CYP3A-mediated metabolic activation, bile-acid transporter inhibition and pharmacogenomic variation. Conversely, in MASLD and cirrhosis, atorvastatin did not worsen liver injury and reduced liver-related events. Severe atorvastatin-associated liver injury is rare but recognizable. Structured monitoring, causality assessment and injury phenotyping are essential, same-drug rechallenge should be avoided, and hydrophilic statins preferred. Statin therapy should not be withheld in chronic liver disease.

PMID 43032608
阅读全文 →
PubMedInternational journal of molecular sciences2026-11-14

Synergistic Anti-Zika Activity of Repurposed Statin and Clofibrate Combinations: Evidence from Oleic Acid-Mediated Metabolic Complementation.

Lee Chung-Do CD, Park Sang-Ik SI, Lee Gun G, Moon Hyeon Jeong HJ et al.

Zika virus (ZIKV) substantially relies on host lipid metabolism, presenting a prime target for host-directed antivirals. To identify host-directed antiviral interventions while circumventing interferon-mediated transcriptomic masking, we curated a dual-virus (dengue and ZIKV) gene signature to query the Connectivity Map. Top lipid-lowering candidates were validated using a reporter virus (rZIKV-Venus) and an authentic wild-type (WT) ZIKV in Vero E6 cells-a model deliberately selected for its interferon deficiency to isolate pure metabolic responses. Dose-response screening of 67 prioritized compounds identified atorvastatin, rosuvastatin, and clofibrate as potent ZIKV inhibitors. Statin-clofibrate combinations exhibited strong synergy, with fractional inhibitory concentration index (FICI) values of 0.203 (atorvastatin-clofibrate) and 0.117 (rosuvastatin-clofibrate) for the 4:1 clofibrate-to-statin ratio and an optimized selectivity index. Mechanistically, exogenous oleic acid supplementation induced significant metabolic complementation, significantly restoring both host lipid droplet (LD) abundance and ZIKV replication readouts suppressed by the dual treatment. Relative LD intensity strongly correlated with viral intensity in both models (Pearson r = 0.951 and 0.956, respectively; both p < 0.0001). These findings demonstrate that concurrent pharmacological modulation of host lipid metabolism exerts synergistic anti-ZIKV effects, highlighting highly curated transcriptomic repurposing as a mechanistic prioritization strategy for host-directed antiviral discovery.

PMID 43027889
阅读全文 →

注册免费账户还可查看另外 9625 篇文献

免费注册查看全部文献 →

了解更多rosuvastatin + ezetimibe